- Home
- EDF vs FENC Comparison
EDF vs FENC Comparison
Compare EDF & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDF
- FENC
- Stock Information
- Founded
- EDF 2010
- FENC 1996
- Country
- EDF United States
- FENC United States
- Employees
- EDF N/A
- FENC N/A
- Industry
- EDF Investment Managers
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EDF Finance
- FENC Health Care
- Exchange
- EDF Nasdaq
- FENC Nasdaq
- Market Cap
- EDF 148.8M
- FENC 156.9M
- IPO Year
- EDF N/A
- FENC 2001
- Fundamental
- Price
- EDF $5.06
- FENC $6.09
- Analyst Decision
- EDF
- FENC Strong Buy
- Analyst Count
- EDF 0
- FENC 2
- Target Price
- EDF N/A
- FENC $14.00
- AVG Volume (30 Days)
- EDF 160.6K
- FENC 120.6K
- Earning Date
- EDF 01-01-0001
- FENC 03-10-2025
- Dividend Yield
- EDF 13.14%
- FENC N/A
- EPS Growth
- EDF N/A
- FENC N/A
- EPS
- EDF N/A
- FENC N/A
- Revenue
- EDF N/A
- FENC $47,538,000.00
- Revenue This Year
- EDF N/A
- FENC $28.99
- Revenue Next Year
- EDF N/A
- FENC $63.21
- P/E Ratio
- EDF N/A
- FENC N/A
- Revenue Growth
- EDF N/A
- FENC 123.69
- 52 Week Low
- EDF $3.51
- FENC $3.96
- 52 Week High
- EDF $5.50
- FENC $11.29
- Technical
- Relative Strength Index (RSI)
- EDF 44.83
- FENC 39.43
- Support Level
- EDF $5.07
- FENC $6.25
- Resistance Level
- EDF $5.16
- FENC $6.90
- Average True Range (ATR)
- EDF 0.09
- FENC 0.34
- MACD
- EDF -0.01
- FENC -0.04
- Stochastic Oscillator
- EDF 34.09
- FENC 19.82
About EDF Virtus Stone Harbor Emerging Markets Income Fund of Beneficial Interest
Virtus Stone Harbor Emerging Markets Income Fund is a closed-end management investment company. Its investment objective is to maximize total return, which consists of income from its investments and capital appreciation. The Fund normally will invest at least 80% of its net assets (plus any borrowings for investment purposes) in emerging markets securities.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.